

ADDENDUM: New Improvement Activity for the 2020 MIPS Performance Year

IA_ERP_3: COVID-19 Clinical Trials

Improvement Activity	
Activity ID	IA_ERP_3
Subcategory:	Emergency Response and Preparedness
Activity Title:	COVID-19 Clinical Trials
Activity Description:	In order to receive credit for this activity, a MIPS eligible clinician must participate in a COVID-19 clinical trial utilizing a drug or biological product to treat a patient with a COVID-19 infection and report their findings through a clinical data repository or clinical data registry for the duration of their study. For more information on the COVID-19 clinical trials, we refer readers to the U.S. National Library of Medicine website .
Weighting:	High
Validation:	Proof of participation in the COVID-19 clinical trial may include a screenshot capture of the MIPS eligible clinician or group's submission to the participating clinical data repository/registry.
Suggested Documentation (inclusive of dates during the selected continuous 90-day or year-long reporting period):	Evidence of submission of clinical data to the clinical data repository or registry supporting the COVID-19 clinical trial (i.e. screenshot from the participating clinical data repository or clinical data registry).
Examples of Additional Activities that Qualify for Attestation:	The type of clinical trial could include designs ranging from the traditional double-blinded placebo-controlled trial to an adaptive design or pragmatic design that flexes to workflow and clinical practice context. It may be conducted in large organized clinical trials led by academic medical centers or healthcare systems. In addition, we intend for this activity to be applicable to MIPS-eligible clinicians that are reporting their COVID-19 related patient data to a clinical data repository, such as Oracle's COVID-19 Therapeutic Learning System .

